(Reuters) – AstraZeneca said on Thursday it had been granted priority review by the U.S. Food and Drug Administration (FDA) for its blockbuster cancer treatment Imfinzi and its effects on patients with a type of limited-stage small cell lung cancer in the United States.
The FDA’s regulatory decision is expected in the fourth quarter of 2024, the Anglo-Swedish drugmaker said.
AstraZeneca’s application was based on positive late-phase data showing the drug had a positive effect on overall survival and progression-free survival in patients with a certain type of lung cancer whose disease had stopped progressing after concomitant platinum-based chemoradiation.
Small cell lung cancer is a very aggressive form of lung cancer.
Imfinzi is a human monoclonal antibody that blocks a tumor’s ability to evade and suppress the immune system, while stimulating the body’s own anti-cancer immune response, providing an alternative to chemotherapy.
(Written by Yadarisa Shabong in Bangalore, Pauline Foret, edited by Augustin Turpin)
Copyright © 2024 Thomson Reuters
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
